Hospital-acquired Clostridium difficile infection: determinants for severe disease

[1]  Lorien S. Dalrymple,et al.  The risk of infection-related hospitalization with decreased kidney function. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  Henry E. Wang,et al.  Chronic Kidney Disease and Risk of Death from Infection , 2011, American Journal of Nephrology.

[3]  S. Huhulescu,et al.  Clostridium difficile infection: monoclonal or polyclonal genesis? , 2011, Infection.

[4]  S. Nseir,et al.  The impact of COPD on ICU mortality in patients with ventilator-associated pneumonia. , 2011, Respiratory medicine.

[5]  V. Debari,et al.  Chronic kidney disease as a risk factor for Clostridium difficile infection , 2010, Nephrology.

[6]  E. Kuijper,et al.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  C. Vaishnavi.  Established and potential risk factors for Clostridum difficile infection. , 2009, Indian journal of medical microbiology.

[8]  Joshua A. Doherty,et al.  Clostridium difficile-associated disease and mortality among the elderly critically ill , 2009, Critical care medicine.

[9]  P. Ruutu,et al.  Hospitalizations and Deaths Associated with Clostridium difficile Infection, Finland, 1996–2004 , 2009, Emerging infectious diseases.

[10]  F. Friedenberg,et al.  T2059 Predictors of Serious Complications Due to Clostridium difficile Infection , 2009 .

[11]  S. Huhulescu,et al.  Outbreak of Clostridium difficile 027 infection in Vienna, Austria 2008-2009. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  J. Barkin,et al.  Clostridium difficile associated infection, diarrhea and colitis. , 2009, World journal of gastroenterology.

[13]  T. Eckmanns,et al.  Surveillance of Clostridium difficile-associated diarrhoea with the German nosocomial infection surveillance system KISS (CDAD-KISS). , 2009, International Journal of Antimicrobial Agents.

[14]  T. Eckmanns,et al.  Risk Factors Related to a Hospital-Associated Cluster of Clostridium difficile PCR Ribotype 027 Infections in Germany During 2007 , 2009, Infection Control & Hospital Epidemiology.

[15]  F. Friedenberg,et al.  Predictors of serious complications due to Clostridium difficile infection , 2009, Alimentary pharmacology & therapeutics.

[16]  M. Zilberberg.  Clostridium difficile–related Hospitalizations among US Adults, 2006 , 2009, Emerging infectious diseases.

[17]  E. Kuijper,et al.  Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping , 2008, Journal of medical microbiology.

[18]  M. Kollef,et al.  Increase in Adult Clostridium difficile–related Hospitalizations and Case-Fatality Rate, United States, 2000–2005 , 2008, Emerging infectious diseases.

[19]  S. Huhulescu,et al.  Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007. , 2008, Journal of medical microbiology.

[20]  N. Verlander,et al.  Clinical Severity of Clostridium difficile PCR Ribotype 027: A Case-Case Study , 2008, PloS one.

[21]  D. Musher,et al.  Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[22]  M. Delmée,et al.  Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  Joshua A. Doherty,et al.  Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting. , 2007, Chest.

[24]  V. Debari,et al.  Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. , 2007, Annals of clinical and laboratory science.

[25]  M. Dionne,et al.  A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Bette Jensen,et al.  A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. , 2006, Archives of internal medicine.

[27]  D. Juurlink,et al.  Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  S. Huhulescu,et al.  First isolation of Clostridium difficile PCR ribotype 027 in Austria. , 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[29]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[30]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[31]  L. Lanthier,et al.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  C. Branger,et al.  Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. , 2005, Journal of medical microbiology.

[33]  B. Dale,et al.  Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. , 2003, The Journal of hospital infection.

[34]  R. Enns,et al.  Clostridium difficile-associated diarrhea: predictors of severity in patients presenting to the emergency department. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[35]  J. Hux,et al.  Quantifying the risk of infectious diseases for people with diabetes. , 2003, Diabetes care.

[36]  Marin H Kollef,et al.  Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. , 2002, Chest.

[37]  D. Maki,et al.  The Commonality of Risk Factors for Nosocomial Colonization and Infection with Antimicrobial-Resistant Staphylococcus aureus, Enterococcus, Gram-Negative Bacilli, Clostridium difficile, and Candida , 2002, Annals of Internal Medicine.

[38]  F. Barbut,et al.  Epidemiology of Clostridium difficile-associated infections. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[39]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[40]  D. Bhasin,et al.  Clostridium difficile toxin and faecal lactoferrin assays in adult patients. , 2000, Microbes and infection.

[41]  A. Sharma,et al.  Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  J. Sarma,et al.  Thirty-day mortality of Clostridium difficile infection in a UK National Health Service Foundation Trust between 2002 and 2008. , 2011, The Journal of hospital infection.

[43]  Lennart Sjöberg,et al.  Ahlstrand E , Persson L , Tidefelt U , Söderquist B. Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy. Eur J Clin Microbiol Infect Dis , 2011 .

[44]  J. Stockman.  A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile—Associated Diarrhea With High Morbidity and Mortality , 2007 .

[45]  K. Thennarasu,et al.  Faecal lactoferrin assay as an adjunct to Clostridium difficile diarrhoea. , 2002, Indian journal of pathology & microbiology.

[46]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.